ANIP
ANI Pharmaceuticals, Inc.81.10
-0.41-0.5%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
1.82BP/E (TTM)
50.69Basic EPS (TTM)
1.60Dividend Yield
0%Recent Filings
8-K
ANI board leadership transitions
ANI Pharmaceuticals announced Patrick D. Walsh stepping down as Chairman on November 24, 2025, while serving out his director term until the 2026 annual meeting; no disagreements noted. Thomas J. Haughey, board member since 2018, steps up as new Chairman, with Jeanne A. Thoma taking Audit and Finance Committee chair. Smooth transition bolsters oversight amid rare disease expansion.
8-K
Record Q3 revenues, raised guidance
ANI Pharmaceuticals posted record Q3 net revenues of $227.8 million, up 53.6% year-over-year, powered by Cortrophin Gel's $101.9 million surge (93.8% growth) and generics ramp. Rare Disease now eyes 50% of 2025 total. Guidance jumps: $854-873 million revenue, $221-228 million adjusted EBITDA. Revenue exploded.
10-Q
Q3 FY2025 results
ANI Pharmaceuticals crushed Q3 with net revenues up 53.6% y/y to $227.8M, driven by Cortrophin Gel's 93.8% surge to $101.9M and full-quarter ILUVIEN/YUTIQ ramp to $16.6M post-Alimera close in Sep 2024 for $418.8M (cash/CVRs, $400M intangibles over 12 years, $34.3M goodwill). Operating income flipped to $36.2M from -$20.5M loss, diluted EPS $1.13 vs -$1.27 (reconciles to 21.1M shares). Cash swelled to $262.6M on $154.9M YTD OCF; Term Loan A ($313M net, 6.76% rate, $74.9M revolver available, Sep 2029 maturity) and $316M conv notes (2.25%, 2029) in covenant compliance. Alimera integration clicked. Single-source API reliance lingers.
8-K
Preferred stock fully converted
ANI Pharmaceuticals fully converted its outstanding Series A Convertible Preferred Stock into common shares on September 26, 2025, eliminating all preferred obligations. Ampersand, the holder, first converted 5,000 shares into 120,580 common shares on August 14, 2025, at $41.4662 per share; the remaining 20,000 shares became 482,320 common shares after meeting the mandatory trigger of the stock's volume-weighted average price exceeding 170% of the conversion price over 20 of 30 trading days. This simplifies the capital structure, ending 6.50% cumulative dividends tied to the original $25 million investment from the 2021 Novitium Pharma acquisition. No preferred shares remain.
8-K
ANI unveils strong Q2 results
ANI Pharmaceuticals' CEO Nikhil Lalwani presents at the H.C. Wainwright Global Investment Conference on September 8, 2025, and Morgan Stanley Global Healthcare Conference on September 9, unveiling an updated investor deck. It spotlights robust Q2 2025 results, with total revenues hitting $211M—up 53% year-over-year—fueled by Cortrophin Gel's $82M surge and 98% Rare Disease growth. Guidance holds steady: $818-843M net revenue and $213-223M adjusted non-GAAP EBITDA for 2025. Supply chain risks linger from single-source manufacturing.
IPO
Employees
Sector
Industry
AMPH
Amphastar Pharmaceuticals, Inc.
25.61-0.70
AMRX
Amneal Pharmaceuticals, Inc.
12.17-0.29
ANIK
Anika Therapeutics Inc.
9.51-0.06
AYTU
Aytu BioPharma, Inc.
2.42+0.09
BIOE
Bio Essence Corp.
0.05+0.00
CPHI
China Pharma Holdings, Inc.
1.44-0.09
ELTP
Elite Pharmaceuticals, Inc.
0.50+0.00
NIKA
NIKA PHARMACEUTICALS INC.
0.28+0.00
NXEN
Nexien BioPharma, Inc.
0.00+0.00
UPC
Universe Pharmaceuticals Inc
3.68+0.05